L3VLUP
ProSign in

MIRM · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MIRMVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MIRM
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMIRMVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 20201 holders, $1.7m30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 20221 holders, $7.5m22 holders, $18.4bn
Q4 20221 holders, $7.0m28 holders, $18.4bn
Q1 20232 holders, $26m26 holders, $21.4bn
Q2 20232 holders, $24m27 holders, $24.7bn
Q3 20233 holders, $87m33 holders, $24.3bn
Q4 20232 holders, $68m32 holders, $28.6bn
Q1 20242 holders, $75m31 holders, $29.8bn
Q2 20243 holders, $179m29 holders, $33.4bn
Q3 20243 holders, $192m27 holders, $33.5bn
Q4 20243 holders, $211m26 holders, $28.5bn
Q1 20253 holders, $251m21 holders, $35.4bn
Q2 20254 holders, $304m21 holders, $32.3bn
Q3 202510 holders, $609m22 holders, $25.9bn
Q4 20258 holders, $613m26 holders, $31.8bn
Q1 202611 holders, $1.1bn25 holders, $31.8bn
Q2 202610 holders, $1.6bn26 holders, $34.6bn
MIRM

Mirum Pharmaceuticals Inc

Holders
10
Reported value
$609m
Buyers
6
Sellers
2

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MIRM (5)

Farallon Capital Management LLC, PDT Partners LLC, Point72 Asset Management LP, Polen Capital Management LLC, Two Sigma Advisers LP

Only VRTX (17)

AllianceBernstein LP, ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →